The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical pharmacology and therapy

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.clpt.2005.08.003PMID 16321621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1

  2005cited by this paper
• Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.

  2004cited by this paper
• Using pharmacogenetics to improve drug safety and efficacy.

  2004cited by this paper
• Lipid-lowering response to statins is affected by CYP3A5 polymorphism.

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.

  2004cited by this paper
• Cardiovascular pharmacogenetics in the SNP era

  2003cited by this paper
• Risk for myopathy with statin therapy in high-risk patients.

  2003cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cited by this paper
• CYP3A5 variant allele frequencies in Dutch Caucasians.

  2002cited by this paper
• Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

  2002cited by this paper
• Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.

  2002cited by this paper
• A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

  2002cited by this paper
• Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.

  2002cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein

  2001cited by this paper
• Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.

  2001cited by this paper
• Statin‐associated myopathy

  2001cited by this paper
• HMG‐CoA reductase inhibitors and P‐glycoprotein modulation

  2001cited by this paper
• Drug interactions of the statins and consequences for drug selection.

  2001cited by this paper
• How Well Tolerated Are Lipid-Lowering Drugs?

  2001cited by this paper
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)

  2001cited by this paper
• The evolving role of statins in the management of atherosclerosis.

  2000cited by this paper
• In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.

  1997cited by this paper
• The physiological function of drug-transporting P-glycoproteins.

  1997cited by this paper
• An E-M algorithm and testing strategy for multiple-locus haplotypes.

  1995cited by this paper
• A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies.

  1991cited by this paper
• On measures of gametic disequilibrium.

  1988cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review

  2025cites this paper
• Therapeutic Potential of Simvastatin: Cellular Mechanism, Binding Energetics, and Resistance Developments.

  2025cites this paper
• Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.

  2025cites this paper
• Pharmacokinetics and lipid-lowering efficacy affected by polymorphisms in genetic variability in statin therapy

  2025cites this paper
• Molecular markers of treatment irregularity of statins: influence of polymorphisms in SLCO1B1 and SLCO1B3.

  2025cites this paper
• The Genetic Blueprint of Cardiovascular Therapy: Pharmacogenomics for Improved Efficacy and Safety

  2024cites this paper
• When the same treatment has different response: The role of pharmacogenomics in statin therapy.

  2023cites this paper
• What are the benefits and drawbacks of statins in carotid artery disease? A perspective review

  2023cites this paper
• Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study

  2023influential citation
• Pharmacogenomics of Statins: A View from ChatGPT.

  2023cites this paper
• EDC-DTI: An end-to-end deep collaborative learning model based on multiple information for drug-target interactions prediction.

  2023cites this paper
• Approach to the Patient with a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.

  2023cites this paper
• Practical Guide to Honest Causal Forests for Identifying Heterogeneous Treatment Effects.

  2023cites this paper
• Cardiovascular precision medicine – A pharmacogenomic perspective

  2023cites this paper
• Sintomatología muscular asociada a estatinas: ¿mito o realidad?

  2022cites this paper
• Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia

  2022cites this paper
• Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review

  2022cites this paper
• Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients

  2022cites this paper
• Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety.

  2022cites this paper
• Statin-associated muscle symptoms: Myth or reality?

  2022cites this paper
• Pharmacogenetics to guide cardiovascular drug therapy

  2021cites this paper
• Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis

  2021cites this paper
• Genetic Polymorphism of Drug‐Metabolizing Enzymes and Drug Transporters in Drug Toxicity

  2021cites this paper
• Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts

  2021cites this paper
• Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report

  2021cites this paper
• Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia

  2021cites this paper
• Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records

  2021cites this paper
• Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis

  2020cites this paper
• Pharmacogenetics of Statin-Induced Myotoxicity

  2020cites this paper
• Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin

  2020cites this paper
• Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters.

  2020cites this paper
• Genetic Risk Factors for Statin-Associated Muscle Symptoms (SAMS)

  2020cites this paper
• Pharmacogenomics in Latin American Populations

  2019cites this paper
• Pharmacogenomic Testing for Postoperative Pain Optimization Before Total Joint Arthroplasty: A Focus on Drug-Drug-Gene Interaction with Commonly Prescribed Drugs and Prior Opioid Use.

  2019cites this paper
• ABCB1 variants (C1236T, rs1128503 and G2677T/A, rs2032582) do not show an association with recurrence and survival in patients with breast cancer undergoing anthracycline-based chemotherapy

  2019cites this paper
• Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components

  2019cites this paper
• Multiplex allele-specific PCR to determine genotypes at statin metabolizing SNP loci- rs1135840 and rs776746

  2019cites this paper
• Statins: a role in breast cancer therapy?

  2018cites this paper
• Personalized rosuvastatin therapy in problem patients with partial statin intolerance

  2018cites this paper
• Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

  2018cites this paper
• Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence

  2018cites this paper
• Pharmacogenetics of Cardiovascular Disease: Genetic Variation and Statin Intolerance

  2018cites this paper
• Genetic variation in statin intolerance and a possible protective role for UGT1A1.

  2018cites this paper
• Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects

  2018cites this paper
• ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics

  2018cites this paper
• Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery

  2018cites this paper
• The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence

  2018influential citation
• Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients

  2018cites this paper
• Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects

  2018cites this paper
• Pharmacogenetic implications in the management of metabolic diseases in Brazilian populations

  2018influential citation
• The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.

  2017cites this paper
• Risikogene bei Myopathien und mitochondrialen Erkrankungen

  2017cites this paper
• Genetic polymorphisms as predictive markers for statin therapy: a route to improved cardiovascular patient outcomes?

  2017cites this paper
• CONNECTION OF THE GENETIC POLYMORPHISM CYP3A5 AND SLCO1B1 WITH THE MUSCULAR SYMPTOMS, CAUSED BY SIMVASTATIN IN PATIENTS WITH CHD, ETHNIC UZBEKS: RESULTS OF THE CASE-CONTROL STUDY

  2017cites this paper
• Myotoxicity of statins: Mechanism of action

  2017cites this paper
• Statin-associated muscle toxicity : clinical and genomic perspectives

  2017influential citation
• Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins

  2017influential citation
• [Risk genes in myopathies and mitochondrial diseases].

  2017cites this paper
• Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia

  2017cites this paper
• Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease

  2017cites this paper
• Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge

  2017cites this paper
• DISTRIBUTION OF POLYMORPHISMS OF GENES OF STATINS METABOLISM AND TRANSPORT IN THE LIVER IN PATIENTS WITH CORONARY ARTERY DISEASE ETHNIC UZBEKS WITH SIMVASTATIN INTOLERANCE

  2017cites this paper
• Seventeen years of statin pharmacogenetics: a systematic review.

  2016cites this paper
• The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?

  2016cites this paper
• Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins.

  2016cites this paper
• Genetic factors in statin intolerance

  2016cites this paper
• Genetic variability of CYP3A4 in a heterogeneous Brazilian population from Maranhão.

  2016cites this paper
• Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis

  2016cites this paper
• Utjecaj genskih polimorfizama na terapijski učinak statina

  2016cites this paper
• Molecular mechanisms of statin intolerance

  2016cites this paper
• Candidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol‐Lowering Response to Simvastatin

  2016cites this paper
• Genetic and immunologic susceptibility to statin-related myopathy.

  2015cites this paper
• Investigation of the association between genetics, drug exposure and statin-induced muscle toxicity

  2015cites this paper
• ESR1 polymorphisms and statin therapy: a sex-specific approach

  2015cites this paper
• Dermatomyositis, polymyositis and immune-mediated necrotising myopathies.

  2015cites this paper
• Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations

  2015cites this paper
• Development and applications of physiologically-based pharmacokinetic models for population data analyses

  2015cites this paper
• Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population.

  2015cites this paper
• Combining Multiple Knowledge Sources: A Case Study of Drug Induced Liver Injury

  2015cites this paper
• Drug–drug interactions that interfere with statin metabolism

  2015cites this paper
• ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis

  2015influential citation
• Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid

  2015cites this paper
• Genetic association study of plasma creatine kinase levels in the Montreal Heart Institute Hospital Cohort

  2015cites this paper
• THE PHARMACOGENETICS OF CARDIOVASCULAR DRUGS

  2014cites this paper
• Statin myotoxicity: a review of genetic susceptibility factors.

  2014cites this paper
• The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis.

  2014cites this paper
• Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients

  2014cites this paper
• Statins and breast cancer prognosis: evidence and opportunities.

  2014cites this paper
• Effect of Pitavastatin on Vascular Reactivity in Hypercholesterolemic Rabbits

  2014cites this paper
• Role of Pharmacogenetics on Response to Statins: A Genotype-based Approach to Statin Therapy Outcome

  2014cites this paper
• Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants

  2014cites this paper
• The pharmacogenomics of statins.

  2014cites this paper
• Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2

  2014cites this paper
• Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians

  2014cites this paper
• Genetic association study of plasma creatine kinase levels in the Montreal Heart

  2014cites this paper
• The pharmacology of statins.

  2014cites this paper